新辅助化疗在进展期胃癌治疗中的临床应用及探讨

Clinical Application of Neoadjuvant Chemotherapy for Advanced Gastric Cancer

目的探讨新辅助化疗在进展期胃癌治疗中的临床应用效果。方法选择该院于2012年1月—2014年1月收治的胃癌患者90例作为研究对象,把90例胃癌患者随机均分为两组,一组为对照组,患者仅在术后给予常规辅助化疗,另一组为观察组,患者不仅术后给予常规辅助化疗,术前要增加新辅助化疗,对两组患者术后毒性反应与术后复发率、生存率进行对比分析。结果观察组根治性切除术占86.7%,全胃切除术占17.8%,近端胃大部切除术占17.8%,远端胃大部切除术占53.3%,姑息性手术占15.6%;对照组根治性切除术占64.4%,全胃切除术占31.1%,近端胃大部切除术占8.9%,远端胃大部切除术占28.9%,姑息性手术占31.1%。观察组实施胃癌根治术患者明显高于对照组。两组对比差异有统计学意义。结论新辅助化疗应用进展期胃癌治疗,可以更好的控制患者病情进展,有效降低肿瘤复发率。

Objective To observe the clinical effect of neoadjuvant chemotherapy in the treatment of advanced gastric cancer.Methods 90 cases of gastric cancer patients of our hospital from 2012 January to 2014 January were selected as the research object and randomly divided into two groups, one group as the control group, patients were only given adjuvant chemotherapy after surgery, another group as the observation group, patients with postoperative adjuvant chemotherapy, not only to increase preoperative neoadjuvant chemotherapy, the toxicity of two groups of patients with postoperative reaction and the postoperative recurrence rate, survival rate were analyzed. Results The rate of radical resection, total gastrectomy, proximal subtotal gastrectomy, distal stomach subtotal gastrectomy, palliative operation of the observation was 86.7%, 17.8%, 17.8%, 53.3%, 15.6%, respectively; while those of the control group was 64.4%, 31.1%, 8.9%, 28.9%, 31.1%,respectively.The patients undergoing gastric cancer radical observation group was obviously more than that of control group, and the difference between the two groups was statistically significant.Conclusion Neoadjuvant chemotherapy in the treatment of advanced gastric cancer can better monitor the disease and effectively reduce the tumor recurrence.